As a first step to address one of these issues, successful in vitro gene therapy of hyperactivated T cells has been shown with PBMCs from MUNC13‐4 deficient patients with active HLH (Dettmer et al, 2019). Here, UNC13D is linked to hemophagocytic syndrome.